Building an Internal Library of RWE Precedents by Therapeutic Area The emergence of Real-World Evidence (RWE) as a legitimate component of the regulatory landscape necessitates the establishment of comprehensive internal libraries that catalog precedents relevant to specific therapeutic areas. This article serves as a detailed, step-by-step tutorial for the development and maintenance of such libraries, particularly in alignment with FDA case studies of approved products supported by RWE. As regulatory professionals in the pharmaceutical and medtech fields strive to ensure compliance with expanding FDA expectations, this resource ultimately aids in fortifying understanding and implementation. Understanding RWE and Its Regulatory Framework…

Lessons from RWE Case Studies Where Regulators Remained Unconvinced Introduction to Real-World Evidence (RWE) in Regulation Real-World Evidence (RWE) has increasingly become a focal point in the regulatory landscape, particularly concerning post-market surveillance and clinical evaluation. By leveraging data from routine clinical practice, RWE can provide insights on treatment effectiveness and safety outside controlled clinical trials. However, the application of RWE in regulatory submissions, especially with the FDA, has been inconsistent, as not all submissions supported by RWE have met regulatory expectations. This tutorial aims to explore notable case studies where the FDA was unconvinced by RWE evidence presented for…

Dissecting RWE Methodology in Landmark FDA Case Study Publications Real-World Evidence (RWE) has increasingly become a pivotal component of the regulatory review process within the US FDA. This article will provide a comprehensive tutorial on the methodology behind RWE case studies that have effectively supported FDA approvals. Regulatory, biostatistics, HEOR, and data standards professionals in pharma and medtech will benefit from this exploration of key FDA case studies, offering insights into RWE precedents, oncology approvals, rare disease registries, and device RWE. Understanding Real-World Evidence and Its Regulatory Context Real-World Evidence refers to the clinical evidence derived from the analysis of…

Future Directions in Publishing and Sharing RWE Case Studies with Regulators In recent years, Real-World Evidence (RWE) has gained significant traction as a valuable tool for informing regulatory decisions. The U.S. Food and Drug Administration (FDA) has indicated a willingness to accept RWE in its review of clinical data to support regulatory approvals. This article serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), and data standards professionals in pharma and medtech. It explores the future directions of publishing and sharing FDA case studies approved products supported by RWE, analyzing regulatory expectations, precedents, and frameworks…

Scenario Planning for Best and Worst Case RWE Review Outcomes As the landscape of pharmaceuticals and medical devices continues to evolve, the significance of Real-World Evidence (RWE) in regulatory submission processes has grown dramatically. Professionals in the fields of regulatory affairs, biostatistics, Health Economics and Outcomes Research (HEOR), and data standards must systematically navigate the complex regulatory expectations established by the FDA, particularly in cases that involve RWE. This article serves as a step-by-step guide on scenario planning for best and worst-case outcomes in RWE reviews, including FDA case studies of approved products supported by RWE. Understanding Real-World Evidence (RWE)…

Incorporating Case Study Insights into Integrated Evidence Planning As regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), Real-World Evidence (RWE), and data standards professionals in pharma and medtech navigate the evolving landscape, the integration of case study insights becomes vital. This tutorial offers a comprehensive, step-by-step guide on how to utilize insights from FDA case studies of approved products supported by RWE. We will outline regulatory expectations and present relevant precedents that can serve as a model for developing integrated evidence plans. Understanding RWE and Its Role in Regulatory Submissions Real-World Evidence is derived from data collected outside of traditional…

Risk Sharing and Outcomes Based Contracts Informed by RWE Case Learnings In recent years, the integration of Real-World Evidence (RWE) into regulatory frameworks has transformed the manner in which pharmaceutical and medical device products are developed, evaluated, and approved. As regulatory bodies like the FDA articulate clearer expectations concerning RWE, the advent of risk-sharing agreements (RSAs) and outcomes-based contracts (OBCs) have emerged as critical strategies to mitigate risk and enhance the value proposition of therapies in the commercial landscape. This article provides a detailed step-by-step tutorial tailored for professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and…

Global comparison of FDA, EMA and HTA RWE case study portfolios Global Comparison of FDA, EMA and HTA RWE Case Study Portfolios Real-World Evidence (RWE) has emerged as a critical component in the regulatory approval process, particularly for the US Food and Drug Administration (FDA) and its counterparts in Europe, such as the European Medicines Agency (EMA) and Health Technology Assessment (HTA) agencies. This article aims to provide a comprehensive and detailed analysis regarding FDA case studies approved products supported by RWE, along with comparable insights from EMA and HTA perspectives. For professionals involved in regulatory compliance, biostatistics, health economics…

Data Use Agreements and BAAs for Claims, EHR and Registry Collaborations As the healthcare landscape evolves, the integration of real-world evidence (RWE) generation into regulatory frameworks has become crucial. Particularly, data use agreements (DUAs) and business associate agreements (BAAs) play a significant role in ensuring compliance with governance, privacy, and HIPAA standards. This article serves as a comprehensive tutorial for professionals in the pharmaceutical, biotechnology, and medical technology fields, providing insights into securing governance, privacy, and HIPAA compliance in RWE generation. Understanding Data Use Agreements (DUAs) Data Use Agreements (DUAs) serve as formal contracts between parties that outline how data…

Institutional review board IRB oversight for observational RWE studies Institutional Review Board (IRB) Oversight for Observational RWE Studies As real-world evidence (RWE) continues to gain prominence in pharmaceutical and biotechnology research, understanding the role of Institutional Review Boards (IRB) in overseeing observational studies is critical for compliance with regulatory requirements. This tutorial provides a step-by-step guide to navigating IRB oversight for observational RWE studies, with a focus on governance, privacy, and HIPAA compliance. 1. Understanding RWE and the Role of IRB Real-world evidence refers to evidence derived from the analysis of real-world data (RWD), which captures the experiences of patients…